Skip to content

NGS-Based Assay of Blood Samples of Sepsis Patients for Rapid Bacterial Identification

Development Of A Non-Interventional Diagnostic Ngs-Based Assay Of Blood Samples Of Sepsis Patients For Rapid Bacterial Identification Based On Next Generation Sequencing.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06141395
Acronym
BIOARTE
Enrollment
100
Registered
2023-11-21
Start date
2023-11-16
Completion date
2024-03-14
Last updated
2024-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pyelonephritis, Bacteremia, Biliary Tract Infection, Pneumonia

Keywords

Bacterial Infection, Antimicrobial susceptibility testing, Next generation sequencing, Blood culture, Time to pathogen identification

Brief summary

Rapid detection of microorganisms is a promising approach towards early administration of appropriate antibiotics for sepsis. This study aims to investigate the potential of a new NGS platform for the rapid diagnosis of circulating bacteria in blood.

Detailed description

Early start of antimicrobials is the cornerstone of management of critically ill patients. The appropriate time window for this early intervention may vary greatly, but it is considered to be one to 3 hours from hospital admission. However, the choice of the antimicrobials for early intervention relies on empirical selection and may several times be inappropriate due to the emergence of antimicrobial resistance. The only way to overcome this difficulty is guidance through early microbial identification and antibiotic susceptibility testing (AST). However, blood cultures are positive in almost 20% of critically ill patients and AST may delay as much as 72 hours. This means that another type of approach is warranted which will tackle the major limitation of standard-of-care (SoC) microbiology, namely, the need to incubate whole blood into flasks enriched with growth media which necessitates subculturing once a blood flask turns positive. It is evident that rapid identification of the pathogen followed by AST using whole blood without the need of blood culture can be a major advance in the diagnostic field. The present study is based on previous analysis of ethylenediaminetetraacetic acid (EDTA) whole blood coming from patients with known bloodstream infection. Next generation sequencing (NGS) of bacterial DNA extracted from whole blood managed to identify the correct pathogen. This study is aiming at the validation of this NGS -based assay in a broader number of patients.

Interventions

DIAGNOSTIC_TESTNGS-based assay for bacterial identification

A total volume of 26ml of whole blood will be sampled from each enrolled patient for three consecutive days. This will be used for Standard-of-Care (SoC) culture and Next Generation Sequencing (NGS), for identification of circulating microorganisms.

Sponsors

The BioArte
CollaboratorUNKNOWN
Hellenic Institute for the Study of Sepsis
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age equal to or above 18 years. * Both genders. * Written informed consent provided by the patient or by one first-degree relative/spouse in case of patients unable to consent. * Patients with high suspicion of infection with at least one sign of the quick SOFA score (i.e. one of mental confusion, more than 22 breaths per minute or systolic blood pressure less than 100mmHg).

Exclusion criteria

* Age below 18 years. * Denial for written informed consent. * Patients already receiving antibiotics. * Pregnancy or lactation.

Design outcomes

Primary

MeasureTime frameDescription
The rate of matching between the results of Next Generation Sequencing and the Standard-of-Care culture for patients with sepsis.7 daysThis will be done by assessing the sensitivity, the specificity, the positive predictive value and the negative predictive value of Next Generation Sequencing and Standard-of-Care. For the analysis of this diagnostic performance, the results of the SoC cultures will be considered the gold standard for comparisons.

Secondary

MeasureTime frameDescription
Difference in time to identification of the bacterial pathogen between Next Generation Sequencing and the Standard-of-Care culture7 daysThe time from start of incubation until final identification will be recorded and compared between the two methods.
Difference in time to Antibiotic Susceptibility Testing between Next Generation Sequencing and the Standard-of-Care culture7 daysThe time from start of incubation until the Antibiotic Susceptibility Testing will be recorded and compared between the two methods.

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026